

- ►► First integrated diagnostic score meeting requirements of international guidelines: combination of liver stiffness measurement (FibroScan®) and blood markers (FibroMeterTM)
 - Best algorithm to identify and manage patient from early to advanced fibrosis: maximized & consistent AUROCs performance across fibrosis stages (F2, F3, F4)
 - Optimal solution to confirm fibrosis stage assessment without liver biopsy: improved balance of Positive Predicitve Value and Negative Predictive Value






FibroMeter VCTE[™] is in vitro diagnostic medical device as defined by Directive 98/79/EC. These scores, based on blood parameters, are useful tools for diagnosing and measuring the extent of liver fibrosis in patients with chronic liver disease of viral (including HIV co-infection), alcohol-related, or metabolic origin. Products in the FibroScan[®] range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. FibroScan[®] examinations must be performed only by an operator who is certified by the manufacturer or its approved local representative. You are expressly recommended to carefully read the guide and the instructions given in the User Manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. This marketing tool is not intended for circulation in the United States. FibroScan[®] and FibroMeter VCTE[™] are registered trademarks of Echosens[™].



Maximized & consistent performance across fibrosis stages (F2, F3, F4)


Performances in NAFLD patients (N = 225)




Ducancelle, J Clin Gastroenterology, 2017

Optimal balance of diagnostic PPV & NPV

FibroScan[®] alone (LSM) and FibroMeter VCTE (FibroScan[®] + FibroMeter[™]) negative and positive predictive value (N=215)



First-in-class clinical performance: FibroMeter VCTE[™] outperforms other fibrosis tests Performances in NAFLD patients for advanced fibrosis F≥3 (N = 410)



AUROcs of tests for advanced fibrosis by kleiner F. Calès, poster #SAT279 ILC (EASL) 2019